

# UCSF

## UC San Francisco Previously Published Works

### Title

HLA-DRB1 and -DQB1 Alleles, Haplotypes and Genotypes in Emirati Patients with Type 1 Diabetes Underscores the Benefits of Evaluating Understudied Populations

### Permalink

<https://escholarship.org/uc/item/0z47h2q1>

### Authors

Yafei, Zain Al  
Mack, Steven J  
Alvares, Marion  
[et al.](#)

### Publication Date

2022

### DOI

10.3389/fgene.2022.841879

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



# HLA-DRB1 and -DQB1 Alleles, Haplotypes and Genotypes in Emirati Patients with Type 1 Diabetes Underscores the Benefits of Evaluating Understudied Populations

## OPEN ACCESS

### Edited by:

Tina Bharani,  
Thomas Jefferson University Hospital,  
Jefferson University Hospitals,  
United States

### Reviewed by:

Narinder K. Mehra,  
All India Institute of Medical Sciences,  
India  
Amal Bishara,  
Hadassah Medical Center, Israel  
Faming Zhu,  
Blood Center of Zhejiang Province,  
China  
Avneesh Gautam,  
Brigham and Women's Hospital and  
Harvard Medical School, United States

### \*Correspondence:

Gehad ElGhazali  
gelghazali@union71.ae

### Specialty section:

This article was submitted to  
Immunogenetics,  
a section of the journal  
Frontiers in Genetics

Received: 22 December 2021

Accepted: 31 January 2022

Published: 24 March 2022

### Citation:

Al Yafei Z, Mack SJ, Alvares M, Ali BR,  
Afandi B, Beshyah SA, Sharma C,  
Osman W, Mirghani R, Nasr A,  
Al Remithi S, Al Jubeh J, Almawi WY,  
AlKaabi J and ElGhazali G (2022) HLA-  
DRB1 and -DQB1 Alleles, Haplotypes  
and Genotypes in Emirati Patients with  
Type 1 Diabetes Underscores the  
Benefits of Evaluating  
Understudied Populations.  
Front. Genet. 13:841879.  
doi: 10.3389/fgene.2022.841879

Zain Al Yafei<sup>1</sup>, Steven J. Mack<sup>2</sup>, Marion Alvares<sup>1</sup>, Bassam R. Ali<sup>3</sup>, Bachar Afandi<sup>4</sup>, Salem A. Beshyah<sup>5</sup>, Charu Sharma<sup>6</sup>, Wael Osman<sup>7</sup>, Rajaa Mirghani<sup>8</sup>, Amre Nasr<sup>9</sup>, Sareea Al Remithi<sup>1</sup>, Jamal Al Jubeh<sup>1</sup>, Wasim Y. Almawi<sup>10</sup>, Juma AlKaabi<sup>4,6</sup> and Gehad ElGhazali<sup>1,6\*</sup>

<sup>1</sup>Sheikh Khalifa Medical City, Purehealth, Abu Dhabi, United Arab Emirates, <sup>2</sup>Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States, <sup>3</sup>Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, <sup>4</sup>Department of Internal Medicine, Tawam Hospital, Al Ain, United Arab Emirates, <sup>5</sup>Department of Medicine, Dubai Medical College, Dubai, United Arab Emirates, <sup>6</sup>Department of Internal Medicine, United Arab Emirates University, Al Ain, United Arab Emirates, <sup>7</sup>College of Arts and Sciences, Khalifa University, Abu Dhabi, United Arab Emirates, <sup>8</sup>Higher College of Technology, Abu Dhabi, United Arab Emirates, <sup>9</sup>Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia, <sup>10</sup>Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan

**Background:** HLA class II (DR and DQ) alleles and antigens have historically shown strong genetic predisposition to type 1 diabetes (T1D). This study evaluated the association of *DRB1* and *DQB1* alleles, genotypes, and haplotypes with T1D in United Arab Emirates.

**Materials and Methods:** Study subjects comprised 149 patients with T1D, and 147 normoglycemic control subjects. Cases and controls were Emiratis and were *HLA-DRB1* and *-DQB1* genotyped using sequence-based typing. Statistical analysis was performed using Bridging Immunogenomic Data-Analysis Workflow Gaps R package.

**Results:** In total, 15 *DRB1* and 9 *DQB1* alleles were identified in the study subjects, of which the association of *DRB1\*03:01*, *DRB1\*04:02*, *DRB1\*11:01*, *DRB1\*16:02*, and *DQB1\*02:01*, *DQB1\*03:02*, *DQB1\*03:01*, and *DQB1\*06:01* with altered risk of T1D persisted after correcting for multiple comparisons. Two-locus haplotype analysis identified *DRB1\*03:01~DQB1\*02:01* [0.44 vs. 0.18, OR (95% CI) = 3.44 (2.33–5.1), *P*<sub>c</sub> = 3.48 × 10<sup>-10</sup>]; *DRB1\*04:02~DQB1\*03:02* [0.077 vs. 0.014, OR = 6.06 (2.03–24.37), *P*<sub>c</sub> = 2.3 × 10<sup>-3</sup>] and *DRB1\*04:05~DQB1\*03:02* [0.060 vs. 0.010, OR = 6.24 (1.79–33.34), *P*<sub>c</sub> = 0.011] as positively associated, and *DRB1\*16:02~DQB1\*05:02* [0.024 vs. 0.075, OR = 0.3 (0.11–0.74), *P*<sub>c</sub> = 0.041] as negatively associated with T1D, after applying Bonferroni correction. Furthermore, the highest T1D risk was observed for *DR3/DR4* [0.104 vs. 0.006, OR = 25.03 (8.23–97.2), *P*<sub>c</sub> = 2.6 × 10<sup>-10</sup>], followed by *DR3/DR3* [0.094 vs. 0.010, OR = 8.72 (3.17–25.32), *P*<sub>c</sub> = 3.18 × 10<sup>-8</sup>] diplotypes.

**Conclusion:** While *DRB1* and *DQB1* alleles and haplotypes associated with T1D in Emiratis showed similarities to Caucasian and non-Caucasian populations, several alleles

and haplotypes associated with T1D in European, African, and Asian populations, were not observed. This underscores the contribution of ethnic diversity and possible diverse associations between *DRB1* and *DQB1* and T1D across different populations.

**Keywords:** type 1 diabetes, HLA, haplotypes, Emiratis, ethnicity

## INTRODUCTION

Type I diabetes (T1D) is a complex autoimmune disorder characterized by insulin deficiency resulting from autoimmune destruction of insulin-secreting pancreatic  $\beta$ -cells in genetically predisposed individuals (Eisenbarth, 2010).

The International Diabetes Federation estimates that more than 1.1 million individuals below the age of 20 years are diagnosed with T1D worldwide (International Diabetes Federation, 2019). In this regard, it was reported that the incidence of T1D in children (15 years or younger) varies greatly among different ethnic and racial groups, highlighted by high to intermediate incidence among Europeans e.g., 5.2/100,000 per year in Finland (International Diabetes Federation, 2019; Knip, 2021), and the low incidence among Asians e.g., 1.8/100,000 per year in China (Gong et al., 2015; International Diabetes Federation, 2019). Among Arab populations of the Middle East, it was estimated that there are about 60,000 children with T1D under the age 15 years (Zayed, 2016). Of these, Kuwait and Saudi Arabia rank among the top ten countries worldwide in T1D prevalence, with rates of 44.5/100,000 and 33.5/100,000, respectively (Majeed et al., 2014; Shaltout et al., 2017; International Diabetes Federation, 2019). No reliable data have yet been reported on the T1D incidence in the United Arab Emirates (UAE). While the reason underlying the differences in T1D prevalence rate according to ethnicity and geographical locations is not known (Patterson et al., 2014; IDF 2019), it was suggested that both environmental parameters and genetic influence the initiation of T1D development (Eisenbarth, 2010; Blanter et al., 2019; Xia et al., 2019).

More than 60 genetic loci were reported in the literature as associated with altered T1D susceptibility (Todd et al., 2007; Bergholdt et al., 2012; Xia et al., 2019), of which the Human Leukocyte Antigens (HLA) class II genes contributed to approximately one-half of T1D genetic risk (Noble et al., 1996; Pociot et al., 2010). Individual *DRB1* and *DQB1* alleles, or allelic combinations were associated with the altered risk of T1D, and both susceptible and protective *DRB1*, *DQA1*, and *DQB1* alleles were reportedly implicated with T1D pathogenesis (Noble et al., 1996; Erlich et al., 2008). This was highlighted by the association of *DRB1\*03:01:01~DQB1\*02:01* and *DRB1\*04:01:01~DQB1\*03:02* haplotypes with increased susceptibility to T1D among Bahraini Arabs (Al-Jenaidi et al., 2005). As the frequencies of *HLA* alleles, haplotypes, and genotypes show considerable population and ethnic differences, population studies confirmed that the relationship of *HLA* with T1D also varies according to the geographical location and ethnic background (Al-Jenaidi et al., 2005; Ahmadov et al., 2018; Fawwad et al., 2019; Zabeen et al., 2019). Compared to numerous studies performed on European populations, limited numbers of studies have been

conducted on populations in the Middle East-North Africa (MENA) region (Al-Jenaidi et al., 2005; Noble et al., 2013).

This is the first case-control study investigating the association of *HLA* with T1D in the Emirati population. The present-day UAE national population is characterized by high rates of consanguinity, endogamy, along with sizeable extended families, and tribal community nature (Zayed, 2016). These and other features further justify investigating the association of *HLA*-class II antigens in T1D among Emirati Arabs. In addition to screening individual alleles, we aimed to assess the prevalence of *DRB1~DQB1* haplotype combination in search of specific susceptible and protective haplotypes.

## MATERIALS AND METHODS

### Study Population

The study subjects comprised 149 unrelated patients with T1D and 147 unrelated normoglycemic controls who were recruited from outpatient T1D clinics at Sheikh Khalifa Medical City (Abu Dhabi, UAE) and Tawam Hospital (Al-Ain, UAE). T1D was diagnosed based on clinical features and laboratory findings and on the 1985 World Health Organization (WHO) criteria (WHO Technical Report Series 727; World Health Organization, 1985) and the classification of diabetes mellitus document, WHO, Geneva; 2019 (World Health Organization, 1985; World Health Organisation, 2019). The inclusion criteria were patients who presented with acute symptoms of diabetes (e.g., polyuria, polydipsia and weight loss), had random blood glucose >200 mg/dl (11.1 mmol/L), C-peptide levels of <0.3 mmol/L, and

**TABLE 1 |** Clinical and demographic characteristics of the study population.

Variable	Patients (149)	Control (147)
Age	18.32 ± 7.45 years	19.71 ± 6.93
Gender		
Male	69 (46.2)	65 (44.2)
Female	80 (53.8)	82 (55.8)
Mode of presentation for T1D		
DKA	64 (42.9)	-
Hyperglycemia	68 (45.6)	-
Duration of diabetes	10.51 ± 6.15	-
<5 years	33 (22.1)	-
5–10 years	42 (28.5)	-
>10 years	74 (49.7)	-
HbA1c (%)	8.6 ± 1.9	-
Established autoimmune diseases	23 (17.2)	None
Celiac disease	5 (3.6)	None
Thyroid disease	18 (12.1)	None
Family History of T1D	50 (33.6)	None
Family history of autoimmune diseases	62 (42)	None

had required long term insulin therapy since the time of diagnosis. Exclusion criteria included monogenic diabetes recognized by autosomal dominant mode of inheritance, type 2 diabetes as manifested by obesity and signs of insulin resistance, diabetes diagnosed before the age of 12 months or chronic diseases (especially autoimmune diseases) and patients/guardians who were unable to provide consent to participate in the study. Control individuals consisted of university students and healthy children with normal fasting/random blood glucose levels, no family history of T1D or other autoimmune diseases and were matched for age and gender with patients with T1D. Healthy children ( $\leq 16$  years) were enrolled during routine hospital visits for other complaints while medical students (adolescents/adults) were recruited from the Tawam teaching hospital (Al Ain, UAE). For each recruited patient with T1D, a control was matched for age and gender to the extend possible. The mean  $\pm$  SD age were  $18.32 \pm 7.45$  (range 6–26 years) and  $19.71 \pm 6.93$  (6–24) of cases and controls, respectively. Patients with T1D and their controls were Emirati nationals with grandparents born in the United Arab Emirates. **Table 1** presents basic clinical and demographic characteristics of the study population.

This study was performed following the guidelines of the Declaration of Helsinki (1993). The study protocol was approved by the Institutional Review Boards at SKMC (REC-25-10-2016 RS-445) and United Arab Emirates University (AAMDHREC 2016-4255 16-002), and informed consent was acquired from all study subjects or their guardians before performing the study.

## Human Leukocyte Antigen Typing

All samples were analysed in our laboratory, which is a well-established clinical laboratory accredited by both the College of American Pathologists (CAP) and ISO15189. Total genomic DNA was extracted from EDTA-anticoagulated peripheral blood of study subjects using Qiagen DNA Mini kit on automated QIAcube, according to the manufacturer instructions (Qiagen, Hilden, Germany). DNA concentrations were determined using NanoDrop-2000 (Wilmington, DE, United States), and *HLA-DRB1* and *-DQB1* genotyping was performed by sequence-based typing (SBT), using GenDx AlleleSEQR kits (GenDx, <https://www.gendx.com/>, Netherland). Based on the method, exon 2 was sequenced for *HLA-DRB1* (AlleleSEQR *HLA-DRB1*, product code 08K63-03), and exon 2 and 3 were sequenced for *HLA-DQB1* (AlleleSEQR *HLA-DQBQ1*, product code 08K64-03). All reagents necessary for primary amplification and sequencing were included in the *HLA-DRB1* and *-DQB1* AlleleSEQR SBT kits (GenDx, Netherland). Briefly, following the primary amplification using 9700 thermal cycler (Applied Biosystems, United States), the PCR products were purified by ExoSAP-IT and the PCR products were sequenced using BigDye Terminatory chemistry and the ABI-3130 genetic sequencer (Applied Biosystems, Foster City, CA). Finally, the sequence data were analysed using the GenDx SBTengine *HLA* typing software ([http://www.gendx.com/product\\_line/sbtengine/](http://www.gendx.com/product_line/sbtengine/)), as described in the manufacturer's protocol. Quality control measures consisted of randomly-chosing

10% of cases and control samples for retyping; concordance was 100%. In addition, six samples from the CAP External Quality Control Proficiency testing program were used to ensure control for the genotyping procedures.

## Statistical Analysis

The association of *HLA-DRB1* and *-DQB1* alleles and haplotypes with T1D was analysed using the Bridging Immunogenomic Data-Analysis Workflow Gaps (BIGDAWG) package (version 2.1) (Pappas et al., 2016), with 95% confidence intervals (CI), odds ratios (OR), and *p*-values (*P*) reported. BIGDAWG's haplotype estimation function, which required the R "haplo.stats" package (version 1.7.7), was also used. Allele counts  $< 5$  in study subjects were collapsed automatically through BIGDAWG into "binned" category (Pappas et al., 2016). The same analyses were performed at the haplotype level, which were estimated by the expectation-maximization (EM) approach (Dempster et al., 1977), and haplotypes with counts of three or fewer were binned. The corrected *p* values (*P<sub>c</sub>*) for multiple comparisons were calculated using the Benferroni method. Analysis of Hardy-Weinberg equilibrium (HWE) deviations for specific haplotypes and individual loci was performed using PyPop (version 0.8.0), and Guo and Thompson's exact method was used in identifying significant locus-level HWE deviations (Guo and Thompson, 1992; Lancaster et al., 2007). Individual haplotype deviations from HWE expectations were determined by Chen's method (Guo and Thompson, 1992), at a significance of 0.05.

The pould (phased or unphased LD) R package (version 0.10.4.9000) (<https://cran.r-project.org/package=pould>) (Osoegawa et al., 2019) was used to calculate  $D'$ ,  $W_n$ ,  $W_{a/b}$ , and  $W_{b/a}$  global linkage disequilibrium (LD) values for *DRB1~DQB1* haplotypes (Thomson and Single 2014), in the range of 0 (equilibrium) to 1 (linkage). In LD,  $D'$  signifies the weighted average of normalized disequilibrium ( $D_{ij}$ ) values, and it is less sensitive to variation across haplotypes of polymorphic loci than the other measures. Moreover,  $W_n$  indicates a correlation coefficient describing the association between alleles at two loci. The conditional asymmetric LD (ALD) measures, including  $W_{a/b}$  and  $W_{b/a}$ , extend the  $W_n$  measure for variation at one locus (a) conditioned on the variation at the second (b) (Single et al., 2016).

## RESULTS

### Deviation From HWE

There was no deviation from HWE at *DRB1* and *DQB1* loci among controls, and no HWE deviation for *DRB1* locus in patients, however, the *DQB1* locus indicated an overall deviation from HWE ( $p = 0.0006$ ) in patients. No trend toward excess heterozygosity or homozygosity was detected in patients. This deviation was due to the presence of five rare *DQB1* genotypes—*DQB1\*02:03+DQB1\*03:04* [1 observed (obs); 0.0268 expected (exp);  $p = 0.0271$ ], *DQB1\*03:03+DQB1\*04:01* (1 obs; 0.0067 exp;  $p = 0.0073$ ), *DQB1\*02:03+DQB1\*06:03* (1 obs; 0.0403 exp;  $p = 0.0388$ ), *DQB1\*06:03+DQB1\*06:03* (1 obs 0.0151 exp;  $p = 0.0106$ ), and *DQB1\*05:01+DQB1\*06:09* (1 obs; 0.0469 exp;  $p = 0.0358$ ).

**TABLE 2** | Associations of *DRB1* alleles with T1D in Emirati study subjects.

Allele	Patient <sup>a</sup>	Control <sup>a</sup>	OR (95%CI)	p-value	<i>P</i> <sub>corrected</sub> <sup>b</sup>
01:01	4 (0.013) <sup>c</sup>	7 (0.024)	0.56 (0.12–2.22)	0.349	NA
01:02	5 (0.017)	8 (0.027)	0.61 (0.16–2.15)	0.386	NA
03:01	132 (0.44)	55 (0.187)	3.46 (2.35–5.11)	$2.1 \times 10^{-11}$	<b><math>3.2 \times 10^{-10}</math></b>
04:02	24 (0.081)	4 (0.014)	6.35 (2.14–25.44)	$1.3 \times 10^{-4}$	<b><math>2.0 \times 10^{-3}</math></b>
04:03	6 (0.02)	15 (0.051)	0.38 (0.12–1.06)	0.042	0.630
04:05	24 (0.081)	8 (0.027)	3.13 (1.33–8.19)	$4.0 \times 10^{-3}$	0.060
07:01	25 (0.084)	31 (0.105)	0.78 (0.43–1.4)	0.370	NA
10:01	6 (0.020)	13 (0.044)	0.44 (0.14–1.28)	0.096	NA
11:01	1 (0.003)	13 (0.044)	0.07 (0–0.49)	$1.0 \times 10^{-3}$	<b>0.015</b>
11:04	1 (0.003)	10 (0.034)	0.1 (0–0.68)	$6.0 \times 10^{-3}$	0.086
13:02	1 (0.003)	10 (0.034)	0.1 (0–0.68)	$6.0 \times 10^{-3}$	0.086
15:01	3 (0.01)	12 (0.041)	0.24 (0.04–0.9)	0.017	0.227
15:02	2 (0.007)	10 (0.034)	0.19 (0.02–0.91)	0.018	0.238
16:01	18 (0.060)	16 (0.054)	1.12 (0.53–2.39)	0.754	NA
16:02	7 (0.023)	23 (0.078)	0.28 (0.1–0.7)	$2.0 \times 10^{-3}$	<b>0.030</b>

<sup>a</sup>Study subjects comprised 149 T1D patients and 147 normoglycemic healthy controls. Significant differences are reported in bold.

<sup>b</sup>*P*<sub>corrected</sub> = corrected p value, calculated as  $P \times n$ , where  $n$  = number of comparisons.

<sup>c</sup>Number (frequency).

**TABLE 3** | Associations of *DQB1* alleles with T1D in Emirati study subjects.

Allele	T1D patient <sup>a</sup>	Control <sup>a</sup>	OR (95%CI)	p-value	<i>P</i> <sub>corrected</sub> <sup>b</sup>
02:01	142 (0.48) <sup>c</sup>	57 (0.19)	3.78 (2.58–5.57)	$3.38 \times 10^{-13}$	<b><math>3.04 \times 10^{-12}</math></b>
02:02	26 (0.09)	28 (0.10)	0.91 (0.5–1.65)	0.736	NA
03:01	6 (0.02)	33 (0.11)	0.16 (0.05–0.4)	$6.27 \times 10^{-6}$	<b><math>5.64 \times 10^{-5}</math></b>
03:02	62 (0.21)	23 (0.08)	3.1 (1.82–5.4)	$6.68 \times 10^{-6}$	<b><math>6.01 \times 10^{-5}</math></b>
04:02	2 (0.007)	12 (0.04)	0.16 (0.02–0.72)	$6.00 \times 10^{-3}$	0.053
05:01	14 (0.05)	32 (0.11)	0.4 (0.19–0.8)	$5.00 \times 10^{-3}$	<b>0.044</b>
05:02	28 (0.09)	46 (0.16)	0.56 (0.33–0.95)	0.021	0.174
06:01	1 (0.003)	18 (0.06)	0.05 (0–0.33)	$6.49 \times 10^{-5}$	<b><math>5.84 \times 10^{-4}</math></b>
06:03	3 (0.01)	8 (0.03)	0.36 (0.06–1.54)	0.122	NA

<sup>a</sup>Study subjects comprised 149 T1D patients and 147 normoglycemic healthy controls. Significant differences are reported in bold.

<sup>b</sup>*P*<sub>corrected</sub> = corrected p value, calculated as  $P \times n$ , where  $n$  = number of comparisons.

<sup>c</sup>Number (frequency).

Many of these alleles are observed less than five times in patients or controls (**Supplementary Tables S1, S3**).

## HLA-DRB1 and -DQB1 Allele Frequencies

Significant DRB1 allelic differences were seen between T1D patients and control subjects, 10 of 31 alleles differing significantly ( $p < 0.05$ ). When the Bonferroni correction was applied, differences were significant for only 4, which comprised *DRB1\*03:01* [0.44 vs. 0.187, OR (95% CI) = 3.46 (2.35–5.11),  $P_c = 3.2 \times 10^{-10}$ ] and *DRB1\*04:02* [0.081 vs. 0.014, OR = 6.35 (2.14–25.44),  $P_c = 2.0 \times 10^{-3}$ ], which were higher among patients, and *DRB1\*11:01* [0.003 vs. 0.044, OR = 0.07 (0–0.49),  $P_c = 0.015$ ] and *DRB1\*16:02* [0.023 vs. 0.078, OR = 0.28 (0.1–0.7),  $P_c = 0.030$ ], which were higher in control subjects (**Table 2**). Similarly, significant allelic differences were seen at the *DQB1* locus, 5 of 9 alleles differing significantly after the Bonferroni correction. These comprised *DQB1\*02:01* [0.48 vs. 0.19, OR = 3.78 (2.58–5.57),  $P_c = 3.04 \times 10^{-12}$ ] and *DQB1\*03:02* [0.21 vs. 0.08, OR = 3.1 (1.82–5.40),  $P_c = 6.01 \times 10^{-5}$ ] which were higher

among patients, and *DQB1\*03:01* [0.02 vs. 0.11, OR = 0.16 (0.05–0.40),  $P_c = 5.64 \times 10^{-5}$ ], *DQB1\*05:01* [0.05 vs. 0.11, OR = 0.40 (0.19–0.80),  $P_c = 0.044$ ], and *DQB1\*06:01* [0.003 vs. 0.06, OR = 0.05 (0–0.33),  $P_c = 5.84 \times 10^{-4}$ ], which were higher among control subjects (**Table 3**).

## Distribution of DRB1-DQB1 Haplotypes

In total, 95 distinct *DRB1~DQB1* haplotypes were identified (**Supplementary Table S2**), of which 42 had counts of  $\geq 2$  in controls or patients, and thus were considered common. In total, four individual haplotypes showing a statistically significant association with T1D (**Table 4**). The full list of *DRB1~DQB1* haplotypes that were binned due to low expected counts is given in **Supplementary Table S4**. Higher frequencies of *DRB1\*03:01~DQB1\*02:01* [0.44 vs. 0.18, OR = 3.44 (2.33–5.10),  $P_c = 3.48 \times 10^{-10}$ ], *DRB1\*04:02~DQB1\*03:02* [0.077 vs. 0.014, OR = 6.06 (2.03–24.37),  $P_c = 2.3 \times 10^{-3}$ ], and *DRB1\*04:05~DQB1\*03:02* [0.06 vs. 0.01, OR = 6.24 (1.79–33.34),  $P_c = 0.011$ ] haplotypes, and lower frequency

**TABLE 4** | Association of *DRB1-DQB1* Haplotypes with T1D in Emirati study subjects.

Haplotype	T1D patient <sup>a</sup>	Controls <sup>a</sup>	OR (95%CI)	p-value	<i>P</i> <sub>corrected</sub> <sup>b</sup>
<i>DRB1*01:01~DQB1*05:01</i>	4 (0.013) <sup>c</sup>	7 (0.024)	0.56 (0.12–2.22)	0.35	NA
<i>DRB1*01:02~DQB1*05:01</i>	4 (0.013)	8 (0.027)	0.49 (0.11–1.84)	0.23	NA
<i>DRB1*03:01~DQB1*02:01</i>	130 (0.44)	54 (0.18)	3.44 (2.33–5.1)	$3.16 \times 10^{-11}$	<b><math>3.48 \times 10^{-10}</math></b>
<i>DRB1*04:02~DQB1*03:02</i>	23 (0.077)	4 (0.014)	6.06 (2.03–24.37)	$2.1 \times 10^{-4}$	<b><math>2.3 \times 10^{-3}</math></b>
<i>DRB1*04:03~DQB1*03:02</i>	5 (0.017)	15 (0.051)	0.32 (0.09–0.94)	0.021	0.208
<i>DRB1*04:05~DQB1*03:02</i>	18 (0.060)	3 (0.010)	6.24 (1.79–33.34)	$9.6 \times 10^{-4}$	<b>0.011</b>
<i>DRB1*07:01~DQB1*02:02</i>	21 (0.071)	27 (0.092)	0.75 (0.39–1.42)	0.34	NA
<i>DRB1*10:01~DQB1*05:01</i>	5 (0.017)	13 (0.044)	0.37 (0.1–1.12)	0.05	0.431
<i>DRB1*11:01~DQB1*03:01</i>	1 (0.003)	10 (0.034)	0.1 (0–0.68)	$5.7 \times 10^{-3}$	0.061
<i>DRB1*16:01~DQB1*05:02</i>	18 (0.060)	16 (0.054)	1.12 (0.53–2.39)	0.75	NA
<i>DRB1*16:02~DQB1*05:02</i>	7 (0.024)	22 (0.075)	0.3 (0.11–0.74)	$3.8 \times 10^{-3}$	<b>0.041</b>

<sup>a</sup>Study subjects comprised 149 T1D patients and 147 normoglycemic healthy controls. Significant differences are reported in bold.

<sup>b</sup>*P*<sub>corrected</sub>, = corrected p value for multiple comparisons as per Bonferroni correction method.

<sup>c</sup>Number (frequency).

**TABLE 5** | Associations of *DRB1-DQB1* diplotypes with T1D in the study subjects.

Diplotype <sup>a</sup>	Patient <sup>b</sup>	Control <sup>b</sup>	OR (95% CI)	p-value
03:01–02:01/04:xx–03:02 <sup>c</sup>	31 (0.104) <sup>d</sup>	2 (0.006)	25.03 (8.23–97.2)	<b><math>2.6 \times 10^{-10}</math></b>
03:01–02:01/03:01–02:01	28 (0.094)	3 (0.010)	8.72 (3.17–25.32)	<b><math>3.18 \times 10^{-8}</math></b>
04:xx–03:02/04:xx–03:02	4 (0.013)	0 (0.000)	NA	NA

<sup>a</sup>*DRB1-DQB1/DRB1-DQB1* diplotype.

<sup>b</sup>Study subjects consisted of 149 T1D subjects and 147 normoglycemic control subjects. Significant differences are reported in bold.

<sup>c</sup>xx = HLA-*DRB1\*04* alleles \*04:02 and \*04:05.

<sup>d</sup>Number (frequency).

of *DRB1\*16:02~DQB1\*05:02* haplotype [0.024 vs. 0.075, OR (95% CI) = 0.30 (0.11–0.74), *P*<sub>c</sub> = 0.041] were seen in T1D patients compared to controls. This assigned T1D susceptibility and protective nature to these haplotypes, respectively (Table 4).

### Distribution of *DRB1-DQB1* Diplotypes

Parallel to the differential distribution of 2-locus haplotypes among T1D patients and controls, distinct *DRB1~DQB1* + *DRB1~DQB1* diplotypes were seen in T1D patients. Extensive diversity in the diplotypes identified was seen, and as such we focused on the *DRB1\*03-* and *DRB1\*04-*containing diplotypes for analysis. As shown in Table 5, *DRB1\*03:01~DQB1\*02:01* + *DRB1\*04:02/05~DQB1\*03:02* 0.104 vs. 0.006, OR = 25.03 (8.23–97.20, *p* =  $2.6 \times 10^{-10}$ ) followed by the homozygous *DRB1\*03:01~DQB1\*02:01* + *DRB1\*03:01~DQB1\*02:01* [0.094 vs. 0.01, OR = 8.72 (3.17–25.32), *p* =  $3.18 \times 10^{-8}$ ] were associated with heightened risk for T1D.

### Linkage Disequilibrium Between *DRB1* and *DQB1* Loci

*D'* and *W<sub>n</sub>* values, as well as *W<sub>DRB1/DQB1</sub>* and *W<sub>DQB1/DRB1</sub>* measures, which assess the global linkage disequilibrium (LD) between *DRB1* and *DQB1* loci in T1D patients and control groups are shown in Supplementary Table S5. There were no substantial differences between T1D cases and controls in terms of LD. Strong LD between *DRB1* and *DQB1* loci is illustrated by the high

*D'* measure (0.92 in patients and 0.95 in controls), and to a lesser extent by *W<sub>n</sub>* (0.75 in patients and 0.72 in controls). The ALD measures (*W<sub>DRB1/DQB1</sub>* and *W<sub>DQB1/DRB1</sub>*) dissect the variation on each locus conditioned on the other. Comparison of the *W<sub>DRB1/DQB1</sub>* (0.89 in patients and 0.90 in controls) with *W<sub>DQB1/DRB1</sub>* (0.71 in both groups) indicated less variation among *DRB1* alleles related to *DQB1*, when compared to *DQB1* alleles related to *DRB1*.

## DISCUSSION

The HLA contribution to T1D genetic susceptibility differs between populations and ethnic groups (Noble et al., 2013), largely due to varied frequencies and functional associations of *DRB1* and *DQB1* alleles and haplotypes (susceptible, protective). Key *DRB1* and *DQB1* alleles and haplotypes associated with T1D were reported for Caucasian and non-Caucasian populations (Petrone et al., 2001; Erlich et al., 2008; Ilonen et al., 2009; Noble et al., 2013), which included *DRB1\*03:01*, *DRB1\*04:02*, *DRB1\*04:05*, *DQB1\*02:01*, and *DQB1\*03:02* along with *DRB1\*03:01~DQB1\*02:01* (DR3), *DRB1\*04:02~DQB1\*03:02* (DR4), and *DRB1\*04:05~DQB1\*03:02* haplotypes also observed in this study and studies on other Arab populations from Bahrain, Tunisia, Lebanon and Saudi Arabia (Al-Harbi et al., 2004; Al-Jenaidi et al., 2005; Stayoussef et al., 2009; Manan et al., 2010; El-Amir et al., 2015; Eltayeb-Elsheikh et al., 2020). It is noteworthy that no DR3 or DR4 haplotype linked with T1D

was detected in East and Southeast Asians (Hashimoto et al., 1994; Kawabata et al., 2002).

*DRB1\*04:01~DQB1\*03:02* (0.34% controls frequency) and *DRB1\*04:01~DQB1\*03:01* (not seen in controls) were rare in Emiratis. This was reminiscent of findings in Europeans where *DRB1\*04:01~DQB1\*03:02* haplotype the second susceptibility haplotype, compared to *DRB1\*04:01~DQB1\*03:01* which was protective in Europeans (Erlich et al., 2008; Noble et al., 2013), but not Africans (Onengut-Gumuscu et al., 2019). In our study, the *DRB1\*04:03* allele and *DRB1\*04:03~DQB1\*03:02* haplotype were more prevalent in the healthy controls but were not statistically different after correcting for multiple comparisons. The highest T1D risk in Emiratis was conferred by *DRB1\*04:05~DQB1\*03:02*, *DRB1\*04:02~DQB1\*03:02* and *DRB1\*03:01~DQB1\*02:01* haplotypes. By comparison, the highest risk in European was imparted by *DRB1\*04:05~DQB1\*03:02*, *DRB1\*04:01~DQB1\*03:02*, *DRB1\*04:02~DQB1\*03:02*, and *DRB1\*03:01~DQB1\*02:01* (Erlich et al., 2008).

*DQB1\*03:03*, *DRB1\*08:01*, *DRB1\*08:02*, and *DRB1\*09:01* were rare among patients or controls in the present study. Moreover, *DRB1\*03:02* was rare in the Emirati study population (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019) and European derived populations; and frequent in *DQB1\*04:02*-containing haplotypes in Africans, protecting against T1D (Howson et al., 2013). *DQB1\*04:01*, common in East Asians (Kawabata et al., 2002), is rare in Emiratis (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019). Furthermore, several *DRB1~DQB1* haplotypes associated with T1D in Europeans, Asians, and Africans were not observed here. For example, the *DRB1\*04:05~DQB1\*02:01* haplotype predisposed to T1D susceptibility in African Americans, while the African DR3 (*DRB1\*03:02~DQB1\*04:02*) haplotype was protective (Noble et al., 2013). In addition to DR3 (*DRB1\*03:01~DQB1\*02:01*) and DR4 (*DRB1\*04~DQB1\*03:02*, *DRB1\*08:01~DQB1\*04:02*) is a T1D predisposing haplotype in Europeans (Thomson et al., 2007). The African *DRB1\*03:02~DQB1\*04:02* and *DRB1\*04:05~DQB1\*02:01* haplotypes were rare in our study and in European populations. The *DQB1\*04:02* allele was more prevalent in the Emirati healthy controls but was not statistically different after correcting for multiple comparisons. *DRB1\*xx:xx~DQB1\*04:02* haplotypes were detected at low counts. The *DRB1\*08:02~DQB1\*03:02*, *DRB1\*09:01~DQB1\*03:03*, and *DRB1\*04:05~DQB1\*04:01* haplotypes, associated with increased T1D susceptibility in East Asians (Ikegami et al., 2008; Katahira et al., 2009), were rare in the current study population (**Supplementary Tables S2, S4**). The *DRB1\*04:05~DQB1\*04:01* haplotype common in East Asia populations (Japanese, Taiwanese, Philippines), is rare in Europeans and African Americans (Thomson et al., 2007), in line with the findings here. On the other hand, *DRB1\*09:01~DQB1\*03:03*, also rare in African Americans, is found in Europeans and East Asians (Thomson et al., 2007). It should be noted that a unique (DR9) *DRB1\*09:01~DQA1\*03:01~DQB1\*02:02* haplotype (but not the *DRB1\*09:01~DQB1\*03:03*) haplotype has been detected in Africans (Noble et al., 2013).

While high prevalence of *DRB1\*07:01~DQB1\*02:02* was seen in controls (9.18%) and cases (7.05%), no significant difference in its distribution between cases and controls was seen. *DRB1\*07:*

*01~DQA1\*02:01~DQB1\*02:02* conferred some protection against T1D in Europeans (Erlich et al., 2008), while *DRB1\*07:01~DQA1\*03:01~DQB1\*02:02* was susceptible for T1D in Africans (Noble et al., 2013). Varied T1D risk of DR7-containing haplotypes was dependent on the *DQA1* allele contained in the *DRB1\*07:01~DQA1\*xx:xx~DQB1\*02:02* haplotype. Noble et al. (2013) showed that the *DRB1\*07:01~DQB1\*03:03* haplotype was protective of T1D in Europeans but was rare in Africans; this haplotype is rare in the current study (0.34% in both groups). Moreover, the distribution of *DRB1\*01:01~DQB1\*05:01*, *DRB1\*01:02~DQB1\*05:02*, *DRB1\*16:01~DQB1\*05:02*, and *DRB1\*10:01~DQB1\*05:01* haplotypes were comparable between T1D cases and controls. While *DRB1\*01:01/01:02~DQB1\*05:01* was shown earlier to be associated with increased susceptibility to T1D (Thomson et al., 2007), this was not consistent with subsequent studies (Erlich et al., 2008). The *DRB1\*16:02~DQB1\*05:02* haplotype was protective for T1D while *DRB1\*11:01~DQB1\*03:01* and *DRB1\*10:01~DQB1\*05:01* were more prevalent in the healthy controls but were not statistically different after correcting for multiple comparisons. *DRB1\*15:01~DQB1\*06:02*, *DRB1\*14:01~DQB1\*05:03*, and *DRB1\*07:01~DQB1\*03:03* (Noble et al., 1996; Petrone et al., 2001; Noble et al., 2011) are protective in Europeans but were observed at low frequencies in the present study and were binned (Supplemental S2 and S4). *DRB1\*15:01~DQB1\*06:02* was seen in approximately 20% of Europeans, but in only 1% of T1D individuals (Noble et al., 1996). *DRB1\*16:02~DQB1\*05:02* is common in controls (7.48%) and patients (2.35%), but is rare in Europeans, Africans, and Asians (Hashimoto et al., 1994). *DRB1\*16:01~DQB1\*05:02*, a common DR2 haplotype in the studied population (6.04 and 5.44% in patients and controls, respectively), was not associated with T1D. In addition, *DRB1\*15:01~DQB1\*06:02*, a T1D protective haplotype in most ethnicities (Osoegawa et al., 2019), was detected at low frequency in patients (0.67%) and controls (1.67%). Moreover, the (protective) *DRB1\*15:03~DQB1\*06:02*, *DRB1\*08:04~DQB1\*03:01*, and *DRB1\*03:02~DQB1\*04:02* African haplotypes were rare in our study population.

Differential contribution of DR~DQ haplotypes to T1D risk were recognized; this was dictated by the specific ethnic background. Most of our T1D patients carried (*DRB1\*03:01~DQB1\*02:01*) (DR3) or (*DRB1\*04:02/05~DQB1\*03:02*) (DR4) haplotypes (87%), and 23% of these were carriers of the heterozygous DR3/DR4 diplotype. In particular, the *DRB1\*03:01~DQB1\*02:01/DRB1\*04:02/05~DQB1\*03:02* (heterozygous) diplotype imparted the highest T1D risk, followed by *DRB1\*03:01~DQB1\*02:01/DRB1\*03:01~DQB1\*02:01* (homozygous) diplotype. This was comparable to Europeans, where most (90%) T1D patients were DR3 or DR4 carriers, with 40% carrying the DR3/DR4 diplotype (Ronningen et al., 1991; Noble et al., 1996), which is higher than the 12% DR3/DR4 diplotype carrier rate seen in Africans (Noble et al., 1996). Furthermore, the highest risk for T1D in Europeans was conferred by the DR3/DR4 diplotype, rather than DR3/DR3 (Noble et al., 1996; Hermann et al., 2003; Erlich et al., 2008), while in East Asians, the highest T1D risk was conferred by the DR4/DR9 diplotype (Ikegami et al., 2008). This absence of

DR3 might explain the low prevalence of T1D in these populations, as suggested earlier (Ikegami et al., 2008).

The apparent discrepancies between our results and those of other populations can be attributed to several factors, including race/ethnicity, incidence of T1D, sample size, genotyping methods, and other factors (Park, 2007; Polychronakos and Li 2011). This was highlighted by the HLA allele/haplotype frequencies between our population and Europeans, Africans, and East Asians (Al-Yafei et al., 2019; Arnaiz-Villena et al., 2019). This in turn explains, at least in part, the variations in T1D prevalence and incidence (Patterson et al., 2012). The high LD values between *DRB1* and *DQB1* loci were found in Emiratis, consistent with the findings in other ethnic groups. LD values were similar in cases and controls, and were identical for  $W_{DQB1/DRB1}$ , suggesting equivalent diversity of *DQB1* alleles within *DRB1*~*DQB1* haplotypes between the groups. The intermediate  $W_n$  LD measure value relative to  $W_{DRB1/DQB1}$  and  $W_{DQB1/DRB1}$  measures in patients illustrates the importance for applying the ALD measures for highly polymorphic genetic systems.

## CONCLUSION

The highest T1D risk was imparted by the *DRB1*\*03:01~*DQB1*\*02:01/*DRB1*\*04:02-05~*DQB1*\*03:02 diplotype followed by the *DRB1*\*03:01~*DQB1*\*02:01/*DRB1*\*03:01~*DQB1*\*02:01 diplotype. Emiratis showed similarities with and differences from European, Asian, and African populations in terms of HLA-*DRB1* and -*DQB1* alleles and haplotypes and their associations with T1D. However, our study had some shortcomings, namely the relatively small sample size, and lack of *DQA1* genotyping (especially for DR7+ samples). An interesting dimension of ethnic diversity and possible diverse relationships is highlighted between HLA-*DRB1* and -*DQB1* genes and T1D across different populations.

## DATA AVAILABILITY STATEMENT

All sequences were submitted to the Short Read Archive (SRA) at GenBank and assigned BioSample accession numbers between SAMN26674334 and SAMN26674604 under BioProject PRJNA609073.

## ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Boards at SKMC (REC-25-10-

## REFERENCES

Ahmadov, G. A., Govender, D., Atkinson, M. A., Sultanova, R. A., Eubova, A. A., Wasserfall, C. H., et al. (2018). Epidemiology of Childhood-Onset Type 1 Diabetes in Azerbaijan: Incidence, Clinical Features, Biochemistry, and HLA-*DRB1* Status. *Diabetes Res. Clin. Pract.* 144, 252–259. doi:10.1016/j.diabres.2018.09.009

2016 RS-445) and United Arab Emirates University (AAMDHREC 2016-4255 16-002). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

## AUTHOR CONTRIBUTIONS

ZA, GE, JA and BRA draft the idea of the research and the research proposal. MA and CS conducted the laboratory and genetic analysis. RM and AN did data cleaning. SM, WO and WA conducted the data analysis, prepared the tables and contributed to the writing of the statistical components of the study. ZA wrote the first draft of the manuscript under supervision of GE. BA, SB, SA, JA, RM and AN contributed to participant's recruitment and reviewed the manuscript. RM, AN and WO prepare the manuscript for publication. All authors reviewed the final version of the manuscript and gave approval for submission for publication of this manuscript.

## FUNDING

This work was funded by the College of Medicine and Health Sciences; United Arab Emirates University grant code 21M103-4 IRCA. This work was also supported by National Institutes of Health (NIH) National Institute of Allergy and Infectious Disease (NIAID) grant R01AI28775 (SM). The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIAID, NIH or United States Government.

## ACKNOWLEDGMENTS

The authors are most grateful to all the patients and parents/guardians who for participation to the study, all physicians, diabetes educators and nurses who helped identification of appropriate patients, and admin and technical staff for data entry and support.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fgene.2022.841879/full#supplementary-material>

Al-Yafei, Z., Goery, T., Alvares, M., Al Seiri, M., Sanchez-Mazas, A., and Elghazali, G. (2020). United Arab Emirates: Unusual Departure from Neutrality towards Excess of Homozygotes at the HLA-B Locus. *HLA* 95 (5), 470–473. doi:10.1111/tan.13774

Al-Harbi, E. M., Abbassi, A.-J., Tamim, H., al-Jenaidi, F., Kooheji, M., Kamal, M., et al. (2004). Specific HLA-*DRB* and -*DQB* Alleles and Haplotypes Confer Disease Susceptibility or Resistance in Bahraini Type 1 Diabetes Patients. *Clin. Vaccin. Immunol* 11 (2), 292–296. doi:10.1128/cdli.11.2.292-296.2004



- Al-Jenaidi, F. A., Wakim-Ghorayeb, S. F., Al-Abbasi, A., Arekat, M. R., Irani-Hakime, N., Najm, P., et al. (2005). Contribution of Selective HLA-DRB1/dqb1 Alleles and Haplotypes to the Genetic Susceptibility of Type 1 Diabetes Among Lebanese and Bahraini Arabs. *J. Clin. Endocrinol. Metab.* 90 (9), 5104–5109. doi:10.1210/jc.2005-1166
- Arnaiz-Villena, A., Yafei, Z. A., Juarez, I., Palacio-Gruber, J., Mahri, A. A., Alvares, M., et al. (2019). HLA Genetic Study from United Arab Emirates (UAE), Abu Dhabi. *Hum. Immunol.* 80 (7), 421–422. doi:10.1016/j.humimm.2019.04.013
- Bergholdt, R., Brorsson, C., Palleja, A., Berchtold, L. A., Fløyel, T., Bang-Berthelsen, C. H., et al. (2012). Identification of Novel Type 1 Diabetes Candidate Genes by Integrating Genome-wide Association Data, Protein-Protein Interactions, and Human Pancreatic Islet Gene Expression. *Diabetes* 61 (4), 954–962. doi:10.2337/db11-1263
- Blanter, M., Sork, H., Tuomela, S., and Flodström-Tullberg, M. (2019). Genetic and Environmental Interaction in Type 1 Diabetes: a Relationship between Genetic Risk Alleles and Molecular Traits of Enterovirus Infection? *Curr. Diab Rep.* 19 (9), 82. doi:10.1007/s11892-019-1192-8
- Dempster, A. P., Laird, N. M., and Rubin, D. B. (1977). Maximum Likelihood from Incomplete Data via the EM Algorithm. *J. R. Stat. Soc. Ser. B (Methodological)* 39 (1), 1–22. doi:10.1111/j.2517-6161.1977.tb01600.x
- Eisenbarth, G. S. (2010). Banting Lecture 2009: an Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes. *Diabetes* 59 (4), 759–774. doi:10.2337/db09-1855
- El-Amir, M. I., El-Feky, M. A., Laine, A. P., Härkönen, T., El-Badawy, O., Eltayeb, A. A., et al. (2015). Risk Genes and Autoantibodies in Egyptian Children with Type 1 Diabetes - Low Frequency of Autoantibodies in Carriers of the HLA-DRB1\*04:05-DQA1\*03-DQB1\*02 Risk Haplotype. *Diabetes Metab. Res. Rev.* 31 (3), 287–294. doi:10.1002/dmrr.2609
- Eltayeb-Elshikh, N., Khalil, E., Mubasher, M., Aljurayyan, A., AlHarthi, H., Omer, W. H., et al. (2020). Association of HLA-DR-DQ Alleles, Haplotypes, and Diploypes with Type 1 Diabetes in Saudis. *Diabetes Metab. Res. Rev.* 36 (8), e3345. doi:10.1002/dmrr.3345
- Erlich, H., Valdes, A. M., Noble, J., Carlson, J. A., Varney, M., Concannon, P., et al. (2008). HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk. *Diabetes* 57 (4), 1084–1092. doi:10.2337/db07-1331
- Fawwad, A., Govender, D., Ahmedani, M. Y., Basit, A., Lane, J. A., Mack, S. J., et al. (2019). Clinical Features, Biochemistry and HLA-DRB1 Status in Youth-Onset Type 1 Diabetes in Pakistan. *Diabetes Res. Clin. Pract.* 149, 9–17. doi:10.1016/j.diabres.2019.01.023
- Gong, C., Meng, X., Jiang, Y., Wang, X., Cui, H., Chen, X., et al. (2015). Trends in Childhood Type 1 Diabetes Mellitus Incidence in Beijing from 1995 to 2010: A Retrospective Multicenter Study Based on Hospitalization Data. *Diabetes Technology Ther.* 17 (3), 159–165. doi:10.1089/dia.2014.0205
- Guo, S. W., and Thompson, E. A. (1992). Performing the Exact Test of Hardy-Weinberg Proportion for Multiple Alleles. *Biometrics* 48 (2), 361–372. doi:10.2307/2532296
- Hashimoto, M., Kinoshita, T., Yamasaki, M., Tanaka, H., Imanishi, T., Ihara, H., et al. (1994). Gene Frequencies and Haplotypic Associations within the HLA Region in 916 Unrelated Japanese Individuals. *Tissue Antigens* 44 (3), 166–173. doi:10.1111/j.1399-0039.1994.tb02375.x
- Hermann, R., Turpeinen, H., Laine, A. P., Veijola, R., Knip, M., Simell, O., et al. (2003). HLA DR-DQ-Encoded Genetic Determinants of Childhood-Onset Type 1 Diabetes in Finland: An Analysis of 622 Nuclear Families. *Tissue Antigens* 62 (2), 162–169. doi:10.1034/j.1399-0039.2003.00071.x
- Howson, J. M. M., Roy, M. S., Zeitels, L., Stevens, H., and Todd, J. A. (2013). HLA Class II Gene Associations in African American Type 1 Diabetes Reveal a Protective HLA-DRB1\*03 Haplotype. *Diabet. Med.* 30 (6), 710–716. doi:10.1111/dme.12148
- Ikegami, H., Noso, S., Babaya, N., Hiromine, Y., and Kawabata, Y. (2008). Genetic Basis of Type 1 Diabetes: Similarities and Differences between East and West. *Rev. Diabet. Stud.* 5 (2), 64–72. doi:10.1900/RDS.2008.5.64
- Ilonen, J., Kocova, M., Lipponen, K., Sukarova-Angelovska, E., Jovanovska, A., and Knip, M. (2009). HLA-DR-DQ Haplotypes and Type 1 Diabetes in Macedonia. *Hum. Immunol.* 70 (6), 461–463. doi:10.1016/j.humimm.2009.03.014
- International Diabetes Federation (2019). *IDF Diabetes Atlas*. 9th ed. Brussels: International Diabetes Federation.
- Katahira, M., Maeda, H., Tosaki, T., and Segawa, S. (2009). The Human Leukocyte Antigen Class II Gene Has Different Contributions to Autoimmune Type 1 Diabetes with or without Autoimmune Thyroid Disease in the Japanese Population. *Diabetes Res. Clin. Pract.* 85 (3), 293–297. doi:10.1016/j.diabres.2009.06.007
- Kawabata, Y., Ikegami, H., Kawaguchi, Y., Fujisawa, T., Shintani, M., Ono, M., et al. (2002). Asian-Specific HLA Haplotypes Reveal Heterogeneity of the Contribution of HLA-DR and -DQ Haplotypes to Susceptibility to Type 1 Diabetes. *Diabetes* 51 (2), 545–551. doi:10.2337/diabres.51.2.545
- Knip, M. (2021). Type 1 Diabetes in Finland: Past, Present, and Future. *Lancet Diabetes Endocrinol.* 9 (5), 259–260. doi:10.1016/S2213-8587(21)00074-7
- Lancaster, A. K., Single, R. M., Solberg, O. D., Nelson, M. P., and Thomson, G. (2007). PyPop Update - a Software Pipeline for Large-Scale Multilocus Population Genomics. *Tissue Antigens* 69 (1), 192–197. doi:10.1111/j.1399-0039.2006.00769.x
- Majeed, A., El-Sayed, A. A., Khoja, T., Alshamsan, R., Millett, C., and Rawaf, S. (2014). Diabetes in the Middle-East and North Africa: an Update. *Diabetes Res. Clin. Pract.* 103 (2), 218–222. doi:10.1016/j.diabres.2013.11.008
- Manan, H., Angham, A. M., and Sittelbanat, A. (2010). Genetic and Diabetic Auto-Antibody Markers in Saudi Children with Type 1 Diabetes. *Hum. Immunol.* 71 (12), 1238–1242. doi:10.1016/j.humimm.2010.09.008
- Noble, J. A., Valdes, A. M., Cook, M., Klitz, W., Thomson, G., and Erlich, H. A. (1996). The Role of HLA Class II Genes in Insulin-dependent Diabetes Mellitus: Molecular Analysis of 180 Caucasian, Multiplex Families. *Am. J. Hum. Genet.* 59 (5), 1134–1148.
- Noble, J. A., Johnson, J., Lane, J. A., and Valdes, A. M. (2013). HLA Class II Genotyping of African American Type 1 Diabetic Patients Reveals Associations Unique to African Haplotypes. *Diabetes* 62 (9), 3292–3299. doi:10.2337/db13-0094
- Noble, J. A., Johnson, J., Lane, J. A., and Valdes, A. M. (2011). Race-specific Type 1 Diabetes Risk of HLA-DR7 Haplotypes. *Tissue Antigens* 78 (5), 348–351. doi:10.1111/j.1399-0039.2011.01772.x
- Onengut-Gumuscu, S., Chen, W.-M., Robertson, C. C., Bonnie, J. K., Farber, E., Zhu, Z., et al. (2019). Type 1 Diabetes Risk in African-Ancestry Participants and Utility of an Ancestry-specific Genetic Risk Score. *Diabetes Care* 42 (3), 406–415. doi:10.2337/dc18-1727
- Osoegawa, K., Mack, S. J., Prestegard, M., and Fernández-Viña, M. A. (2019). Tools for Building, Analyzing and Evaluating HLA Haplotypes from Families. *Hum. Immunol.* 80 (9), 633–643. doi:10.1016/j.humimm.2019.01.010
- Pappas, D. J., Marin, W., Hollenbach, J. A., and Mack, S. J. (2016). Bridging Immunogenomic Data Analysis Workflow Gaps (BIGDAWG): An Integrated Case-Control Analysis Pipeline. *Hum. Immunol.* 77 (3), 283–287. doi:10.1016/j.humimm.2015.12.006
- Park, Y. (2007). Functional Evaluation of the Type 1 Diabetes (T1D) Susceptibility Candidate Genes. *Diabetes Res. Clin. Pract.* 77, S110–S115. doi:10.1016/j.diabres.2007.01.043
- Patterson, C. C., Gyűrűs, E., Rosenbauer, J., Cinek, O., Neu, A., Schober, E., et al. (2012). Trends in Childhood Type 1 Diabetes Incidence in Europe during 1989–2008: Evidence of Non-uniformity over Time in Rates of Increase. *Diabetologia* 55 (8), 2142–2147. doi:10.1007/s00125-012-2571-8
- Patterson, C., Guariguata, L., Dahlquist, G., Soltész, G., Ogle, G., and Silink, M. (2014). Diabetes in the Young - a Global View and Worldwide Estimates of Numbers of Children with Type 1 Diabetes. *Diabetes Res. Clin. Pract.* 103 (2), 161–175. doi:10.1016/j.diabres.2013.11.005
- Petrone, A., Bugawan, T. L., Mesturino, C. A., Nisticò, L., Galgani, A., Giorgi, G., et al. (2001). The Distribution of HLA Class II Susceptible/protective Haplotypes Could Partially Explain the Low Incidence of Type 1 Diabetes in continental Italy (Lazio Region). *Tissue Antigens* 58 (6), 385–394. doi:10.1034/j.1399-0039.2001.580607.x
- Pociot, F., Akolkar, B., Concannon, P., Erlich, H. A., Julier, C., Morahan, G., et al. (2010). Genetics of Type 1 Diabetes: What's Next? *Diabetes* 59 (7), 1561–1571. doi:10.2337/db10-0076
- Polychronakos, C., and Li, Q. (2011). Understanding Type 1 Diabetes through Genetics: Advances and Prospects. *Nat. Rev. Genet.* 12 (11), 781–792. doi:10.1038/nrg3069
- Rønningen, K. S., Spurkland, A., Iwe, T., Vartdal, F., and Thorsby, E. (1991). Distribution of HLA-DRB1, -DQA1 and -DQB1 Alleles and DQA1-DQB1 Genotypes Among Norwegian Patients with Insulin-dependent Diabetes

- Mellitus. *Tissue Antigens* 37 (3), 105–111. doi:10.1111/j.1399-0039.1991.tb01854.x
- Shaltout, A. A., Wake, D., Thanaraj, T. A., Omar, D. M., Al-AbdulRazzaq, D., Channanath, A., et al. (2017). Incidence of Type 1 Diabetes Has Doubled in Kuwaiti Children 0-14 Years over the Last 20 Years. *Pediatr. Diabetes* 18 (8), 761–766. doi:10.1111/pedi.12480
- Single, R. M., Strayer, N., Thomson, G., Paunic, V., Albrecht, M., and Maiers, M. (2016). Asymmetric Linkage Disequilibrium: Tools for Assessing Multiallelic LD. *Hum. Immunol.* 77 (3), 288–294. doi:10.1016/j.humimm.2015.09.001
- Stayoussef, M., Benmansour, J., Al-Jenaidi, F. A., Nemr, R., Ali, M. E., Mahjoub, T., et al. (2009). Influence of Common and Specific HLA-Drb1/dqb1 Haplotypes on Genetic Susceptibilities of Three Distinct Arab Populations to Type 1 Diabetes. *Clin. Vaccin. Immunol.* 16 (1), 136–138. doi:10.1128/CVI.00215-08
- Thomson, G., and Single, R. M. (2014). Conditional Asymmetric Linkage Disequilibrium (ALD): Extending the Biallelic R2 Measure. *Genetics* 198 (1), 321–331. doi:10.1534/genetics.114.165266
- Thomson, G., Valdes, A. M., Noble, J. A., Kockum, I., Grote, M. N., Najman, J., et al. (2007). Relative Predispositional Effects of HLA Class II DRB1-DQB1 Haplotypes and Genotypes on Type 1 Diabetes: a Meta-Analysis. *Tissue Antigens* 70 (2), 110–127. doi:10.1111/j.1399-0039.2007.00867.x
- Todd, J. A., Walker, N. M., Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., et al. (2007). Robust Associations of Four New Chromosome Regions from Genome-wide Analyses of Type 1 Diabetes. *Nat. Genet.* 39 (7), 857–864. doi:10.1038/ng2068
- World Health Organisation (2019). *Classification of Diabetes Mellitus*. Geneva: WHO. Licence: CC BY-NC-SA 3.0 IGO <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>
- World Health Organization (1985). *Diabetes Mellitus: Report of a WHO Study Group*. Technical Report Series No. 727. Geneva: WHO.
- Xia, Y., Xie, Z., Huang, G., and Zhou, Z. (2019). Incidence and Trend of Type 1 Diabetes and the Underlying Environmental Determinants. *Diabetes Metab. Res. Rev.* 35 (1), e3075. doi:10.1002/dmrr.3075
- Zabeen, B., Govender, D., Hassan, Z., Noble, J. A., Lane, J. A., Mack, S. J., et al. (2019). Clinical Features, Biochemistry and HLA-DRB1 Status in Children and Adolescents with Diabetes in Dhaka, Bangladesh. *Diabetes Res. Clin. Pract.* 158, 107894. doi:10.1016/j.diabres.2019.107894
- Zayed, H. (2016). Genetic Epidemiology of Type 1 Diabetes in the 22 Arab Countries. *Curr. Diab Rep.* 16 (5), 37. doi:10.1007/s11892-016-0736-4

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Al Yafei, Mack, Alvares, Ali, Afandi, Beshyah, Sharma, Osman, Mirghani, Nasr, Al Remithi, Al Jubeh, Almawi, AlKaabi and ElGhazali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.